Skip to main content

Advertisement

SpringerLink
Log in

Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background and aims

Clinicopathologic and molecular studies have provided new insights and understanding on the pathological events during ovarian carcinogenesis. Moreover, angiotensin II-enhanced tumor cell invasion via type 1 angiotensin II receptor in ovarian cancer cell lines was recently demonstrated. It has been suggested that renin–angiotensin system (RAS) activity increases in diseases involving the female reproductive system. In the present study, we aimed to analyze the possible relationship between the levels of circulating angiotensin-converting enzyme (ACE), an important molecule of RAS, and ovarian cancer (OC).

Materials and methods

This study was conducted in 41 epithelial OC patients (mean age 56.1 ± 10.2 years) and 19 healthy controls (mean age 53.4 ± 13.1 years). Clinical and laboratory features are summarized. Serum ACE and Ca-125 levels were measured using commercially available laboratory kits.

Results

Serum ACE levels of epithelial OC patients and controls were 30.58 ± 13.37 and 14.15 ± 3.67, respectively. Serum ACE levels were significantly elevated in epithelial OC patients in comparison to healthy controls. Ca-125 levels of epithelial OC patients were also significantly elevated in epithelial OC patients. No correlation was observed between ACE levels and Ca-125 levels. In epithelial OC patients, serum ACE levels did not differ according to stages and pathologic subtypes of the patients.

Conclusion

Our results showed that serum ACE levels were increased in OC patients. Being an important component of RAS, circulating ACE might be associated with ongoing pathobiologic events in ovarian carcinogenesis. Therefore, targeting the RAS pathway could provide a future treatment strategy for this cancer type.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dietl J (2014) Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 289:241–246

    Article  PubMed  Google Scholar 

  2. Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z, Li L (2013) Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett 6:28–34

    PubMed Central  PubMed  Google Scholar 

  3. O’Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L (2013) Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res 6:29

    Article  PubMed Central  PubMed  Google Scholar 

  4. Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M (2013) Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Arch Gynecol Obstet 288:859–865

    Article  CAS  PubMed  Google Scholar 

  5. Nolen BM, Lokshin AE (2013) Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther 17:139–146

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Verheijen RH, Cibula D, Zola P, Reed N, Council of the European Society of Gynaecologic Oncology (2012) Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement. Int J Gynecol Cancer 22:170–174

    Article  PubMed  Google Scholar 

  7. Albayrak M, Celebi H, Albayrak A, Sayilir A, Yesil Y, Balcik OS, Yokus O, Celik T (2012) Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma. J Renin Angiotensin Aldosterone Syst 13:259–264

    Article  CAS  PubMed  Google Scholar 

  8. Haznedaroglu IC, Beyazit Y (2010) Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin Angiotensin Aldosterone Syst 11:205–213

    Article  CAS  PubMed  Google Scholar 

  9. Beyazit Y, Ibis M, Purnak T, Turhan T, Kekilli M, Kurt M, Sayilir A, Onal IK, Turhan N, Tas A, Köklü S, Haznedaroglu IC (2011) Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis. Dig Dis Sci 56:2160–2165

    Article  CAS  PubMed  Google Scholar 

  10. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, Nomura S, Kikkawa F (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 94:552–560

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Beyazit Y, Purnak T, Suvak B, Kurt M, Sayilir A, Turhan T, Tas A, Torun S, Celik T, Ibis M, Haznedaroglu IC (2011) Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol 35:644–649

    Article  CAS  PubMed  Google Scholar 

  12. Herr D, Bekes I, Wulff C (2013) Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 4:150

    Google Scholar 

  13. Ager EI, Neo J, Christophi C (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29:1675–1684

    Article  CAS  PubMed  Google Scholar 

  14. Haznedaroglu IC, Beyazit Y (2013) Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clin Sci (Lond) 124:307–323

    Article  CAS  Google Scholar 

  15. Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, Li Q, Xiang Y, Gao B (2012) Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3 K/Akt and MAPK signaling pathways. Oncol Rep 27:783–790

    CAS  PubMed  Google Scholar 

  16. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK (2010) The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59:630–637

    Article  CAS  PubMed  Google Scholar 

  17. Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Capecchi M, Corvol P, Bernstein KE (2000) Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 106:1391–1398

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Erman A, Chen-Gal B, van Dijk DJ, Sulkes J, Kaplan B, Boner G, Neri A (1996) Ovarian angiotensin-converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. J Clin Endocrinol Metab 81:1104–1107

    CAS  PubMed  Google Scholar 

  19. Cotter TP, Kealy NP, Duggan PF, Curtain A, Bredin CP (1997) Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma. Respir Med 91:237–239

    Article  CAS  PubMed  Google Scholar 

  20. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII The angiotensin II receptors. Pharmacol Rev 52:415–472

    PubMed  Google Scholar 

  21. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB (2003) Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 116:61–69

    Article  CAS  PubMed  Google Scholar 

  22. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11:2686–2694

    Article  CAS  PubMed  Google Scholar 

  23. Correa-Noronha SA, Noronha SM, Alecrim C, Mesquita Ade C, Brito GS, Junqueira MG, Leite DB, Carvalho CV, Silva ID (2012) Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer. Gynecol Endocrinol 28:889–891

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Canakkale State Hospital, Canakkale, Turkey

    Fatma Beyazit

  2. Department of Obstetrics and Gynecology, Dr. Zekai Tahir Burak Women Health Education and Research Hospital, Ankara, Turkey

    Sevgi Ayhan & Tayfun Gungor

  3. Department of Biochemistry, Turgut Ozal University Hospital, Ankara, Turkey

    Huseyin Tugrul Celik

Authors
  1. Fatma Beyazit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sevgi Ayhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huseyin Tugrul Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tayfun Gungor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatma Beyazit.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beyazit, F., Ayhan, S., Celik, H.T. et al. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet 292, 415–420 (2015). https://doi.org/10.1007/s00404-015-3661-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-015-3661-x

Keywords

Search

Navigation